Payment overview · 2025
General Payments
$1,266.88
58 reported records · 18 companies
Healthcare provider profile · identity verified
Allen Patrick Tauro, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHARLOTTE, NC · NPI 1083697908
Verified facts
What the public records show
CMS Open Payments records show Allen Patrick Tauro, MD received $1,266.88 in general payments during 2025 across 58 reported records.
Abbott Laboratories accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $249.56 | 19.7% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $197.13 | 15.6% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $137.68 | 10.9% | 7 | 2025 |
| TREACE MEDICAL CONCEPTS, INC. | Unresolved — no canonical attribution shown | $120.51 | 9.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $102.20 | 8.1% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $102.09 | 8.1% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $53.69 | 4.2% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $44.03 | 3.5% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $41.23 | 3.2% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $39.87 | 3.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.65 | 2.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.89 | 2.5% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.67 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.00 | 1.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.78 | 1.6% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $19.88 | 1.6% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $16.33 | 1.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.69 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,266.88 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $225.16 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $152.46 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $152.46 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $124.63 | 6 | 2025 |
Source payment records
|
|||||
| LAPIPLASTY SYSTEM 1 Normalized: lapiplasty system 1 |
Device | TREACE MEDICAL CONCEPTS, INC. | $120.51 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $74.31 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $54.14 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $48.06 | 3 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $44.03 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $41.67 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $41.67 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $41.67 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $41.23 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.85 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.65 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.49 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 75 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 442 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 332 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 303 | 93 |
| Losartan Potassium | Losartan Potassium | 249 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 246 | 70 |
| Omeprazole | Omeprazole | 192 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 52 |
| Metformin Hcl | Metformin Hcl | 150 | 39 |
| Gabapentin | Gabapentin | 146 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 40 |
| Trazodone Hcl | Trazodone Hcl | 116 | 37 |
| Lisinopril | Lisinopril | 114 | 37 |
| Furosemide | Furosemide | 109 | 39 |
| Metformin Hcl Er | Metformin Hcl | 109 | 34 |
| Sertraline Hcl | Sertraline Hcl | 109 | 33 |
| Simvastatin | Simvastatin | 98 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 30 |
| Meloxicam | Meloxicam | 84 | 30 |
| Carvedilol | Carvedilol | 82 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 20 |
| Eliquis | Apixaban | 75 | 19 |
| Tramadol Hcl | Tramadol Hcl | 74 | 20 |
| Ozempic | Semaglutide | 73 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 17 |
| Montelukast Sodium | Montelukast Sodium | 67 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 20 |
| Alprazolam | Alprazolam | 62 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 21 |
| Prednisone | Prednisone | 57 | 49 |
| Allopurinol | Allopurinol | 56 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 30 |
| Jardiance | Empagliflozin | 51 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 13 |
| Synthroid | Levothyroxine Sodium | 50 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 16 |
| Potassium Chloride | Potassium Chloride | 44 | 15 |
| Cephalexin | Cephalexin | 42 | 38 |
| Lorazepam | Lorazepam | 42 | 14 |
| Famotidine | Famotidine | 41 | 14 |
| Irbesartan | Irbesartan | 41 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 35 |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Glimepiride | Glimepiride | 37 | 14 |
| Pregabalin | Pregabalin | 37 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | 18 |
| Methylprednisolone | Methylprednisolone | 35 | 31 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 13 |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 11 |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 22 |
| Azithromycin | Azithromycin | 24 | 20 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 24 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 21 |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 19 |
| Acyclovir | Acyclovir | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 12 |
| Ramipril | Ramipril | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Tobramycin | Tobramycin | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,266.88 · 58 records | Abbott Laboratories | ABRYSVO, ACCRUFER, AIRSUPRA, AMS 700, AREXVY, BREZTRI, Barostim Neo System, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, ETERNA, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, INCEPTIV, JARDIANCE, KRYSTEXXA, LAPIPLASTY SYSTEM 1, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error